← All countries · Europe
94%
MCV1
2025 · WHO/UNICEF estimate
96%
DTP3
2025 · WHO/UNICEF estimate
96%
IPV complete
2025 · WHO/UNICEF estimate
96%
HepB3
2025 · WHO/UNICEF estimate
4
Measles cases
2025 reported
5,308
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 90%2012 · WHO/UNICEF estimate | 90.4% | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 96%2025 · WHO/UNICEF estimate | 95.8% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 96%2025 · WHO/UNICEF estimate | 95.8% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 96%2025 · WHO/UNICEF estimate | 95.8% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 96%2025 · WHO/UNICEF estimate | 95.8% | C · weak | |
| MCV1First dose of measles-containing vaccine | 94%2025 · WHO/UNICEF estimate | 93.8% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 93%2025 · WHO/UNICEF estimate | 93.4% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 94%2025 · WHO/UNICEF estimate | 93.8% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 96%2025 · WHO/UNICEF estimate | 95.8% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 100%2024 · Administrative (country-reported) | 100% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 96%2025 · WHO/UNICEF estimate | 95.8% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 95.7%2025 · Administrative (country-reported) | 95.7% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 96%2025 · WHO/UNICEF estimate | 95.7% | A · strong | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 36%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 21%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 23%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 42025 | 0.7per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 182025 | 3.3per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 5,3082025 | 969.5per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 62025 | 1.1per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 412025 | 7.5per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 22025 | 0.4per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (29 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Adults with chronic conditions, older adults with chronic conditions | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M10 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 4 | Y5 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | Administered only to high risk groups (newborns of HepB positive mothers) |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y12 | HPV administered to females and males | 12-14 years old girls and boys. Vaccine is not part of the regular mandatory vaccination but just recommended free of charge vaccination |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M5-M13 | HPV administered to females and males | 12-14 years old girls and boys. Vaccine is not part of the regular mandatory vaccination but just recommended free of charge vaccination |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons >=59 years |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M14 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y4-Y10 | General/routine | Children born up to the year 2015 (included) get the second dose at 11-th year of life. Children born in 2016 and afterwards should get the second dose at 5-th year of life. |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | M2 | General/routine | 10 and 13 valent vaccines administered; 15 valent vaccine is also available since 2024 |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | M4 | General/routine | 10 and 13 valent vaccines administered; 15 valent vaccine is also available since 2024 |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | M10 | General/routine | 10 and 13 valent vaccines administered; 15 valent vaccine is also available since 2024 |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | 10 and 13 valent vaccines administered; 15 valent vaccine is also available since 2024 |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | 10 and 13 valent vaccines administered; 15 valent vaccine is also available since 2024 |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M10 | General/routine | 10 and 13 valent vaccines administered; 15 valent vaccine is also available since 2024 |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | M2 | General/routine | 10 and 13 valent vaccines administered; 15 valent vaccine is also available since 2024 |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 2 | M4 | General/routine | 10 and 13 valent vaccines administered; 15 valent vaccine is also available since 2024 |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 3 | M10 | General/routine | 10 and 13 valent vaccines administered; 15 valent vaccine is also available since 2024 |
| TDAP_S_IPVTdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine | 5 | Y12 | General/routine | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y30 | Adults | Vaccination in adults when having reached 30 years and than the booster dose every 15 years. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 7 | +Y15 | Adults | Vaccination in adults when having reached 30 years and than the booster dose every 15 years. |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.